J&J lowers 2022 revenue and earnings expectations, stops giving Covid vaccine sales guidance

Submitted by admin on April 19, 2022 - 10:55am

Source:

CNBC

News Tags:

Headline:

snippet:

J&J is now forecasting 2022 sales of $94.8 billion to $95.8 billion, about $1 billion lower than the guidance provided in January.
The company lowered its full-year adjusted earnings per share by 25 cents to between $10.15 and $10.35, from a previous forecast of $10.40 to $10.60.
CFO Joe Wolk, when asked about halting Covid vaccine sales guidance, said the shots are not for profit and do not impact the company’s bottom line.

Search form